Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells.

Freedman JD, Duffy MR, Lei-Rossmann J, Muntzer A, Scott EM, Hagel J, Campo L, Bryant RJ, Verrill C, Lambert A, Miller P, Champion BR, Seymour LW, Fisher KD.

Cancer Res. 2018 Dec 15;78(24):6852-6865. doi: 10.1158/0008-5472.CAN-18-1750. Epub 2018 Nov 18.

PMID:
30449733
2.

Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.

Lei J, Jacobus EJ, Taverner WK, Fisher KD, Hemmi S, West K, Slater L, Lilley F, Brown A, Champion B, Duffy MR, Seymour LW.

J Immunother Cancer. 2018 Jun 13;6(1):55. doi: 10.1186/s40425-018-0350-x.

3.

Dominant influenza A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and 2017/18 seasons, respectively.

Adlhoch C, Snacken R, Melidou A, Ionescu S, Penttinen P; The European Influenza Surveillance Network.

Euro Surveill. 2018 Mar;23(13). doi: 10.2807/1560-7917.ES.2018.23.13.18-00146.

4.

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies.

Rondy M, Kissling E, Emborg HD, Gherasim A, Pebody R, Trebbien R, Pozo F, Larrauri A, McMenamin J, Valenciano M; I-MOVE/I-MOVE+ group.

Euro Surveill. 2018 Mar;23(9). doi: 10.2807/1560-7917.ES.2018.23.9.18-00086.

6.

Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56.

Duffy MR, Alonso-Padilla J, John L, Chandra N, Khan S, Ballmann MZ, Lipiec A, Heemskerk E, Custers J, Arnberg N, Havenga M, Baker AH, Lemckert A.

J Gen Virol. 2018 Jan;99(1):135-147. doi: 10.1099/jgv.0.000978. Epub 2017 Nov 20.

PMID:
29154744
7.

Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.

Scott EM, Duffy MR, Freedman JD, Fisher KD, Seymour LW.

Macromol Biosci. 2018 Jan;18(1). doi: 10.1002/mabi.201700187. Epub 2017 Sep 13. Review.

PMID:
28902983
8.

Making Oncolytic Virotherapy a Clinical Reality: The European Contribution.

Duffy MR, Fisher KD, Seymour LW.

Hum Gene Ther. 2017 Nov;28(11):1033-1046. doi: 10.1089/hum.2017.112. Epub 2017 Aug 1. Review.

PMID:
28793793
9.

Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.

Freedman JD, Hagel J, Scott EM, Psallidas I, Gupta A, Spiers L, Miller P, Kanellakis N, Ashfield R, Fisher KD, Duffy MR, Seymour LW.

EMBO Mol Med. 2017 Aug;9(8):1067-1087. doi: 10.15252/emmm.201707567.

10.

Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus.

Illingworth S, Di Y, Bauzon M, Lei J, Duffy MR, Alvis S, Champion B, Lieber A, Hermiston T, Seymour LW, Beadle J, Fisher K.

Mol Ther Oncolytics. 2017 Mar 29;5:62-74. doi: 10.1016/j.omto.2017.03.003. eCollection 2017 Jun 16.

11.

Defining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction In Vitro in the Presence of Mouse Serum.

Lopez-Gordo E, Doszpoly A, Duffy MR, Coughlan L, Bradshaw AC, White KM, Denby L, Nicklin SA, Baker AH.

J Virol. 2017 May 26;91(12). pii: e02487-16. doi: 10.1128/JVI.02487-16. Print 2017 Jun 15.

12.

Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe.

Kissling E, Rondy M; I-MOVE/I-MOVE+ study team.

Euro Surveill. 2017 Feb 16;22(7). pii: 30464. doi: 10.2807/1560-7917.ES.2017.22.7.30464.

13.

Retargeting FX-binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop.

Robertson S, Parker AL, Clarke C, Duffy MR, Alba R, Nicklin SA, Baker AH.

J Gen Virol. 2016 Aug;97(8):1911-6. doi: 10.1099/jgv.0.000505. Epub 2016 May 16.

14.

Predominance of influenza A(H1N1)pdm09 virus genetic subclade 6B.1 and influenza B/Victoria lineage viruses at the start of the 2015/16 influenza season in Europe.

Broberg E, Melidou A, Prosenc K, Bragstad K, Hungnes O; WHO European Region and the European Influenza Surveillance Network members of the reporting countries.

Euro Surveill. 2016;21(13). doi: 10.2807/1560-7917.ES.2016.21.13.30184.

15.

Albumin and Furosemide Combination for Management of Edema in Nephrotic Syndrome: A Review of Clinical Studies.

Duffy M, Jain S, Harrell N, Kothari N, Reddi AS.

Cells. 2015 Oct 7;4(4):622-30. doi: 10.3390/cells4040622. Review.

16.

Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo.

Ma J, Duffy MR, Deng L, Dakin RS, Uil T, Custers J, Kelly SM, McVey JH, Nicklin SA, Baker AH.

PLoS Pathog. 2015 Feb 6;11(2):e1004673. doi: 10.1371/journal.ppat.1004673. eCollection 2015 Feb.

17.

Start of the 2014/15 influenza season in Europe: drifted influenza A(H3N2) viruses circulate as dominant subtype.

Broberg E, Snacken R, Adlhoch C, Beauté J, Galinska M, Pereyaslov D, Brown C, Penttinen P; WHO European Region and the European Influenza Surveillance Network.

Euro Surveill. 2015 Jan 29;20(4). pii: 21023. No abstract available.

18.

Long QTc Syndrome Type 2 Presenting in a Postpartum Patient on Medroxyprogesterone.

Kern J, Duffy M, Kern C, Mazza V.

Case Rep Cardiol. 2014;2014:676080. doi: 10.1155/2014/676080. Epub 2014 Oct 21.

19.

Management of ganciclovir-resistant cytomegalovirus retinitis in HIV infection in the era of antiretroviral therapy.

Adler H, De Gascun CF, McSweeney F, Acheson RW, Brannigan ET, Duffy M, Keegan DJ, Lambert JS.

Int J STD AIDS. 2014 Oct;25(11):827-9. doi: 10.1177/0956462414522773. Epub 2014 Feb 10.

PMID:
24516078
20.

Identification of novel small molecule inhibitors of adenovirus gene transfer using a high throughput screening approach.

Duffy MR, Parker AL, Kalkman ER, White K, Kovalskyy D, Kelly SM, Baker AH.

J Control Release. 2013 Aug 28;170(1):132-40. doi: 10.1016/j.jconrel.2013.05.007. Epub 2013 May 20.

Supplemental Content

Loading ...
Support Center